Walleye Capital LLC bought a new position in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 52,427 shares of the company’s stock, valued at approximately $159,000.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. RTW Investments LP raised its holdings in Jounce Therapeutics by 63.5% during the first quarter. RTW Investments LP now owns 4,680,412 shares of the company’s stock worth $31,780,000 after acquiring an additional 1,817,214 shares in the last quarter. Deep Track Capital LP increased its position in Jounce Therapeutics by 6.5% during the first quarter. Deep Track Capital LP now owns 4,259,653 shares of the company’s stock worth $28,923,000 after buying an additional 259,653 shares during the last quarter. Cowen AND Company LLC increased its position in Jounce Therapeutics by 395.0% during the second quarter. Cowen AND Company LLC now owns 2,843,149 shares of the company’s stock worth $8,615,000 after buying an additional 2,268,814 shares during the last quarter. Vanguard Group Inc. increased its position in Jounce Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,613,505 shares of the company’s stock worth $10,956,000 after buying an additional 21,473 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Jounce Therapeutics by 5.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,179,953 shares of the company’s stock worth $8,012,000 after buying an additional 61,252 shares during the last quarter. Institutional investors own 86.99% of the company’s stock.
Jounce Therapeutics Trading Down 6.5 %
Jounce Therapeutics stock opened at $0.90 on Friday. The company has a market capitalization of $46.27 million, a price-to-earnings ratio of -0.35 and a beta of 1.21. The stock’s 50 day moving average is $2.17 and its 200-day moving average is $3.23. Jounce Therapeutics, Inc. has a 12 month low of $0.88 and a 12 month high of $8.80.
Analyst Upgrades and Downgrades
JNCE has been the topic of a number of recent analyst reports. StockNews.com raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Robert W. Baird lowered their price target on Jounce Therapeutics to $5.00 in a research report on Tuesday, August 9th. Piper Sandler lowered their price target on Jounce Therapeutics to $6.00 in a research report on Tuesday, September 6th. Raymond James downgraded Jounce Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the stock from $16.00 to $3.00 in a research report on Thursday, November 10th. Finally, HC Wainwright decreased their target price on Jounce Therapeutics from $15.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Jounce Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.40.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.
- Get a free copy of the StockNews.com research report on Jounce Therapeutics (JNCE)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.